APA (7th ed.) Citation

Bruckert, C., Matsushita, K., Mroueh, A., Amissi, S., Auger, C., Houngue, U., . . . Schini-Kerth, V. B. (2022). Empagliflozin prevents angiotensin II-induced hypertension related micro and macrovascular endothelial cell activation and diastolic dysfunction in rats despite persistent hypertension: Role of endothelial SGLT1 and 2. Vascular Pharmacology, 146, N.PAG. https://doi.org/10.1016/j.vph.2022.107095

Chicago Style (17th ed.) Citation

Bruckert, Christophe, et al. "Empagliflozin Prevents Angiotensin II-induced Hypertension Related Micro and Macrovascular Endothelial Cell Activation and Diastolic Dysfunction in Rats Despite Persistent Hypertension: Role of Endothelial SGLT1 and 2." Vascular Pharmacology 146 (2022): N.PAG. https://doi.org/10.1016/j.vph.2022.107095.

MLA (9th ed.) Citation

Bruckert, Christophe, et al. "Empagliflozin Prevents Angiotensin II-induced Hypertension Related Micro and Macrovascular Endothelial Cell Activation and Diastolic Dysfunction in Rats Despite Persistent Hypertension: Role of Endothelial SGLT1 and 2." Vascular Pharmacology, vol. 146, 2022, p. N.PAG, https://doi.org/10.1016/j.vph.2022.107095.